Which biologic targets IL-5 signaling in severe eosinophilic asthma?

Prepare for the PANCE Pulmonology Exam. Use flashcards and multiple choice questions with helpful explanations to boost your knowledge and confidence. Get exam ready!

Multiple Choice

Which biologic targets IL-5 signaling in severe eosinophilic asthma?

Explanation:
IL-5 is the key cytokine that drives eosinophil growth, activation, and survival. Blocking this pathway reduces eosinophilic inflammation in severe asthma. Mepolizumab is a monoclonal antibody that directly neutralizes IL-5, preventing it from binding its receptor on eosinophils and cutting down eosinophil production and survival. In contrast, omalizumab targets IgE; dupilumab blocks IL-4 and IL-13 signaling via the IL-4 receptor alpha; benralizumab binds the IL-5 receptor to deplete eosinophils but does not neutralize IL-5 itself. So the therapy that directly targets IL-5 signaling is Mepolizumab.

IL-5 is the key cytokine that drives eosinophil growth, activation, and survival. Blocking this pathway reduces eosinophilic inflammation in severe asthma. Mepolizumab is a monoclonal antibody that directly neutralizes IL-5, preventing it from binding its receptor on eosinophils and cutting down eosinophil production and survival.

In contrast, omalizumab targets IgE; dupilumab blocks IL-4 and IL-13 signaling via the IL-4 receptor alpha; benralizumab binds the IL-5 receptor to deplete eosinophils but does not neutralize IL-5 itself. So the therapy that directly targets IL-5 signaling is Mepolizumab.

More practice questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy